Cost-Effectiveness of Hybrid Closed Loop Insulin Pumps Versus Multiple Daily Injections Plus Intermittently Scanned Glucose Monitoring in People With Type 1 Diabetes in The Netherlands
Sign Up to like & getrecommendations! Published in 2022 at "Advances in Therapy"
DOI: 10.1007/s12325-022-02058-9
Abstract: Hybrid closed loop (HCL) insulin pump systems and intermittently scanned continuous glucose monitoring (IS-CGM) are increasingly used by individuals with type 1 diabetes (T1D). The aim of the analysis was to compare the long-term cost-effectiveness… read more here.
Keywords: system; closed loop; cost; insulin ... See more keywords
Increased proportion of time in hybrid closed‐loop “Auto Mode” is associated with improved glycaemic control for adolescent and young patients with adult type 1 diabetes using the MiniMed 670G insulin pump
Sign Up to like & getrecommendations! Published in 2019 at "Diabetes"
DOI: 10.1111/dom.13912
Abstract: The Medtronic MiniMed 670G system delivers insulin to patients with type 1 diabetes mellitus (T1DM) using either its hybrid closed‐loop (HCL) “Auto Mode” feature or an open‐loop mode. In this retrospective, cross‐sectional analysis, we quantified… read more here.
Keywords: auto; auto mode; time; type diabetes ... See more keywords
Glycemic outcomes of children 2–6 years of age with type 1 diabetes during the pediatric MiniMed™ 670G system trial
Sign Up to like & getrecommendations! Published in 2022 at "Pediatric Diabetes"
DOI: 10.1111/pedi.13312
Abstract: Highly variable insulin sensitivity, susceptibility to hypoglycemia and inability to effectively communicate hypoglycemic symptoms pose significant challenges for young children with type 1 diabetes (T1D). Herein, outcomes during clinical MiniMed™ 670G system use were evaluated… read more here.
Keywords: 670g system; outcomes children; type diabetes; minimed 670g ... See more keywords
MON-LB052 Efficacy and Safety of Minimed 670G Automode in Children with Type 1 Diabetes Less Than 8 Years Old
Sign Up to like & getrecommendations! Published in 2019 at "Journal of the Endocrine Society"
DOI: 10.1210/js.2019-mon-lb052
Abstract: Abstract Introduction: The Medtronic MiniMed 670G system with SmartGuardTM (Medtronic, Northridge, CA) is a commercial hybrid closed-loop (HCL) system approved for use in 2017 for children >8 years of age. Studies of the system in… read more here.
Keywords: system; time; minimed 670g; children years ... See more keywords
Real-World Data from the MiniMed™ 670G System Commercial Launch
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.2337/db18-960-p
Abstract: The Medtronic MiniMed™ 670G hybrid closed-loop system with SmartGuard™ technology, which automatically adjusts basal insulin delivery, was released for commercial use in the U.S. in March 2017. Data from the first 13,9patients to use the… read more here.
Keywords: mode; system; auto mode; time ... See more keywords
The MiniMed™ 670G Hybrid Closed-Loop (HCL) System and Patient-Reported Outcomes Concerning Quality of Life Measures
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.2337/db18-963-p
Abstract: Patient-reported outcomes are important in assessing the impact of new diabetes therapies on patient perceptions of quality of life (QoL). The QoL of patients using the Medtronic MiniMed™ 670G HCL system with SmartGuard™ technology, released… read more here.
Keywords: reported outcomes; system; minimed 670g; hcl system ... See more keywords
Real-World Data from the MiniMed™ 670G System Commercial Launch—The First 1,052 Patients Using the System for Three Months
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.2337/db18-994-p
Abstract: The Medtronic MiniMed™ 670G hybrid closed-loop system with SmartGuard™ technology was released for commercial use in the U.S. in March 2017. Sensor glucose (SG) and device utilization data from the initial open-loop Manual Mode and… read more here.
Keywords: 670g system; system; self medtronic; patients using ... See more keywords
2405-PUB: Minimed 640G vs. Minimed 670G, a Comparison in Children and Adolescents with Diabetes Type 1
Sign Up to like & getrecommendations! Published in 2019 at "Diabetes"
DOI: 10.2337/db19-2405-pub
Abstract: Introduction: After a long lead-in period, artificial pancreas (AP) technology is well on its way to revolutionizing the treatment of diabetes, but no AP is currently approved. Recently data about the use of a hybrid… read more here.
Keywords: system; time; using 640g; minimed 670g ... See more keywords